Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

  • End date
    Aug 21, 2027
  • participants needed
  • sponsor
    Nationwide Children's Hospital
Updated on 22 August 2021
total cavopulmonary connection


A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.


This investigation is a prospective, open-labeled clinical trial determining the safety of the use of tissue engineered vascular grafts as conduits for EC TCPC. Patients will be monitored for adverse events (AE) and serious adverse events (SAE). Special attention will be paid to the incidence of stenosis. We will determine graft-related morbidity and mortality for the second generation TEVGs which will include any post-operative complication such as any aneurismal dilation, stenosis, thromboembolic or infectious event that requires treatment and is thought to be caused by the graft as determined by the investigators and confirmed by the data safety monitoring board. The graft related complication rates will be compared between the first and second generation TEVGs. An interim analysis will be performed to assess the incidence of early (<6 month) graft-related complications in the first 6 enrolled patients. Safety and tolerability will be assessed through serial imaging, to determine the effect of growth and remodeling on graft performance through echocardiography and 4-dimensional MRI. All appropriate patients requiring EC TCPC who meet study inclusion/exclusion criteria will be evaluated for enrollment in the clinical trial. All enrolled subjects will be required to have follow-up visits at Nationwide Children's Hospital for a minimum of 2 years following implant. After obtaining informed consent for the patient's parents, patients with single ventricle cardiac anomalies will undergo EC TCPC using a tissue engineered conduit. Post-operative care and monitoring will follow an established, standardized, clinical algorithm in which the patient's clinical status including complications and measurements of graft function will be serially evaluated and recorded over a two year period using physical examination, echocardiography, and MRI.

Condition cardiovascular system diseases, Congenital Heart Disease, cardiac diseases, cardiovascular diseases, cardiac disorders, Cardiovascular Abnormalities, Congenital Heart Defect, Male Hormonal Deficiencies/Abnormalities, heart disorder, DILV - Double Inlet Left Ventricle, cardiovascular disorders, Growth Hormone Deficiencies/Abnormalities, Heart Valve Disease, Cardiac Disease, cardiac disorder, Birth Defects, Heart disease, dorv, Double Outlet Right Ventricle, Single Ventricle, Unbalanced AV Canal, Heart Defect, Tricuspid Atresia, cardiovascular disease (cvd), Mitral Atresia, Heart Disease, Female Hormonal Deficiencies/Abnormalities, VALVULAR HEART DISEASE, Cardiovascular Disease, Hypoplastic Left Heart Syndrome, CONGENITAL ANOMALY NOS, heart diseases
Treatment Tissue Engineered Vascular Grafts
Clinical Study IdentifierNCT04467671
SponsorNationwide Children's Hospital
Last Modified on22 August 2021


Yes No Not Sure

Inclusion Criteria

Patients will be eligible for inclusion in the study if they meet all of the following criteria
Patient must be a candidate to undergo an extracardiac total cavopulmonary connection
Patient and/or legal guardian must voluntarily provide informed consent/assent for participation in the study

Exclusion Criteria

Patients will be excluded from participation in the study if they meet any of the following criteria
Patient has an urgent/emergent operative status
Patient has acute renal failure or renal insufficiency in the opinion of the investigator
Patient requires a graft less than 12 mm or greater than 24 mm in diameter
Patient has a pacemaker
Patient has pulmonary vascular resistance greater than 4 um2 (u=Wood's units)
Patient has abnormal venous drainage (interrupted inferior vena cava [IVC])
Patient presents with significant atrio-ventricular valve regurgitation that in the opinion of the investigator, makes them ineligible
Patient has a history of another condition or significant medical problem that, in the opinion of the investigator, precludes compliance with protocol-specified procedures
Patients taking any medications that in the opinion of the Investigator could interfere with the TEVG, including bisphosphonates (i.e. Clodronate or Zoledronate)
Patient or parent/legal guardian is, in the opinion of the investigator, unable to comply with protocol evaluations
Preoperative hemoglobin <11.0 mg/dL at time of patient's pre-admission testing
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note